These engineered receptors usually contain a monoclonal antibodyderived single-chain variable fragment (scFv) that confers specific binding to a tumor antigen

These engineered receptors usually contain a monoclonal antibodyderived single-chain variable fragment (scFv) that confers specific binding to a tumor antigen. stems from recent innovations in the development of CARs. First-generation CARs comprised an antibody-derived scFv followed by hinge, transmembrane, and the CD3 signaling domain PFI-3 name of the T-cell coreceptor.2However, an additional costimulatory signal was found to be required for full activation and long-termin vivofunction of CAR T cells, an observation that formed the basis for improved second-generation CARs.3Early clinical results confirmed increased expansion and persistence in patients with hematologic malignancies, and results were particularly promising for targeting of B-cell malignancies with CD19-specific CAR T cells.4There were anecdotal reports of complete and molecular remission in patients with highly chemotherapy-refractory B-cell malignancies, including a case report from the University of Pennsylvania PFI-3 (UPENN) that provided some of the strongest evidence to date of on-target effects mediated by CD19-targeted CAR T cells.5,6,7 The recent, more mature clinical trial data serve as notice to the entire oncologic research community that CAR T cells have moved into the fast lane. In addition to the high CR rates reported by the three groups (NCI, UPENN, MSKCC), many of the remissions were sustained, suggesting that this therapy could enhance survival either directly or by serving as a bridge therapy to kill off tumor cells until an allogeneic stem cell transplant (allo-SCT, the heretofore only treatment option with potential for cure of certain blood cancers) can be performed. Remarkably, several of the B-ALL patients were infused with allogeneic CD19-targeted CAR T cells following relapse after a prior allo-SCT, but there were no significant graft vs. hostdisease (GVHD) toxicities. This was further explored in two clinical trials from the NCI and PFI-3 BCM that directly evaluated the COG7 safety and efficacy of infusing CD19-targeted CAR T cells as a donor lymphocyte infusion (DLI) in patients with relapsed, refractory B-cell malignancies. There were clear instances of objective responses that notably did not require any form of preconditioning therapy. In addition, there was no evidence of GVHD, which, when paired with the objective responses, suggests that CAR T cells could one day become part of the modern-day allo-SCT regimen. Furthermore, several groups (NCI, UPENN, MSKCC) that extended their work targeting non-Hodgkin’s lymphomas (NHLs) with CD19-targeted CAR T cells reported a modest objective response rate with CR rates <40%, which may be improved when using T cells with increased capacity for self-renewal (such as a central memory phenotype) for a more durable effect. Despite these advances, life in the fast lane still has its velocity bumps. A major clinical concern to any CAR T-cell physician is the poorly understood cytokine release syndrome (CRS), which is usually believed to be secondary to a massive release of cytokine mediators from activated T cells in response to antigen encounter.8,9,10,11Patients often require aggressive support in an intensive care unit setting. Data from B-ALL suggest that tocilizumab, an interleukin-6-receptor blocking antibody, can counteract CRS toxicities, although it is usually unknown whether there will be PFI-3 long-term impact on CAR T-cell function, as there is with steroids, which have been shown to kill CAR T cells.8,10 Other tumor targets remain a challenge. For example, the CR rates for non-Hodgkin's lymphoma have been lower and not very durable, with many patients ultimately relapsing or developing progressive disease. However, improved results when central memory T cells are infused already suggests that the technology can be further refined to increase efficacy. It is also unclear whether the current iteration of second-generation CARs will be sufficient to enable T cells to traffic to and eradicate metastatic solid tumors. Finally, it is not clear whether the success with CD19 targeting can be repeated for other tumor antigens. A particular challenge arises if the target antigen is also expressed at some level PFI-3 in healthy tissues, which could lead to significant off-target toxicities. The adoption of this complex therapy, requiring extensive expertise in gene transfer technology andex vivomanipulation of T cells, into multicenter phase II trials is not trivial. However, such trials are needed to formally evaluate efficacy and could ultimately lead to the first clinical indication of a CAR T-cell therapy, underscoring the importance of trial design and meaningful clinical end points. These trials will also determine whether the clinical experience managing CRS can be transferred to other medical centers, which requires development of appropriate guidelines. Moreover, expansion of CAR T-cell production to additional facilities is needed to meet the growing demand from these trials..